Crinetics Pharmaceuticals CRNX 深 滬
已收盤 02-06 16:00:00 美东时间
45.28
+0.490
+1.09%
華盛通- 最 高46.66
- 今 開45.94
- 成交量 199.68万股
- 最 低 43.935
- 昨 收 44.79
- 總市值 46.42亿
- 52周最高 57.99
- 市盈率 靜 --
- 換手率 1.95%
- 52周最低 24.10
- 委 比 20.72%
- 總股本 1.03亿
- 歷史最高 62.53
- 量 比 1.95
- 振 幅 6.08%
- 歷史最低 10.63
- 每 手 1
- 風險率 7.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crinetics Pharmaceuticals Announces First Patient Dosed In BALANCE-CAH Phase 2/3 Trial Evaluating Investigational Candidate Atumelnant For Proposed Treatment Of Classic CAH In Children And Adolescents
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the first patient has been dosed in the BALANCE-CAH Phase 2/3 trial evaluating investigational candidate atumelnant, a novel, once-daily oral
01-23 05:08
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
<p>Crinetics Pharmaceuticals announced the first patient dosing in the BALANCE-CAH Phase 2/3 trial evaluating atumelnant, a novel, once-daily oral ACTH receptor antagonist for children and adolescents with classic congenital adrenal hyperplasia (CAH). The study aims to address the significant unmet need in this population by correcting elevated androgens while preserving low glucocorticoid doses. Atumelnant is the first-in-class small molecule AC...
01-22 21:05
美股大行评级 | Medline获14家大行首予评级，最高目标价52美元；富国银行上调GOOGL目标价从268美元升至350美元
今日重点评级关注：HC Wainwright & Co.：维持Enlivex Therapeutics"买入"评级，目标价从7美元升至13美元；BTIG：维持Oruka Therapeutics"买入"评级，目标价从63美元升至73美元
01-13 10:18
Goldman Sachs Upgrades Crinetics Pharmaceuticals to Buy, Announces $67 Price Target
Goldman Sachs analyst Richard Law upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Neutral to Buy and announces $67 price target.
01-13 01:09
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Crinetics Pharmaceuticals, Inc. granted stock options and RSUs to 10 new employees under the 2021 Inducement Plan. The stock options (37,575 shares) and RSUs (25,525 units) have an exercise price of $53.25 and vest over four years. Both options and RSUs require continued employment. The company focuses on endocrine disease treatments and has a significant pipeline including PALSONIFY™ for acromegaly.</p>
01-12 21:05
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Crinetics Pharmaceuticals prices offering at $45.95 per share
Crinetics Pharmaceuticals (CRNX) priced an underwritten public offering of 7.62M shares at a price to the public of $45.95 per share. The gross proceeds to Crinetics from the offering are expected to ...
01-07 13:14
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Crinetics Pharmaceuticals announces $350M proposed public offering
Crinetics Pharmaceuticals (NASDAQ:CRNX) on Monday stated that they intended an underwritten public offering of $350M of common stock, subject to market and other conditions, with a 30-day underwriter...
01-06 05:21
